Beijer Alma har genomfört fyra förvärv i år, varav ett under det andra kvartalet.
Redeye is growing more optimistic about the investment case in Oncopeptides after two news items thi...
Finnair reports Q2 results on Jul 16. Industrial action has continued to affect performance, while t...
Redeye comments on Modelons’ proposed directed share issue of SEK20m at SEK20 per share, representin...
Redeye comments on Invisio ahead of Q2-results (due 18 July) where we expect sequential improvement ...
Redeye lifts its ARR and EBITDA-CAPEX estimates for Litium after the Q2 report, where ARR growth sig...
- Report out 18 July - Q2e: sales SEK 37m, -3% y-o-y, EBIT SEK -0.
Redeye positively views yesterday’s press release from Acarix announcing that it has secured its fir...
Coor förväntas redovisa en något lägre omsättning, men förbättrade marginaler tack vare lägre person...
Redeye provides a short comment on the trading update from Cheffelo, released this morning.
- SEK 72m follow-up order (Terminals) from Swedish FMV - Deliveries start in Q3 - Could add ~10% to ...
Active Biotech har tagit ett steg närmre ett partnerskap i och med slutförandet av LION-studien.
Redeye comments on Vertiseit’s acquisition of MDT. As the price is reasonable and the SEK20m in ARR ...
Redeye comments on Isofol’s recently announced rights issue outcome.
According to the press release yesterday, the Board of Directors and Julian Read came to the mutual ...
